Wall Street analysts expect Inotiv, Inc. (NASDAQ:NOTV) to announce ($0.08) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Inotiv’s earnings. Inotiv also reported earnings per share of ($0.08) during the same quarter last year. The company is expected to announce its next quarterly earnings report on Friday, August 13th.
According to Zacks, analysts expect that Inotiv will report full-year earnings of ($0.18) per share for the current fiscal year. For the next financial year, analysts forecast that the business will post earnings of $0.74 per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Inotiv.
Inotiv (NASDAQ:NOTV) last posted its earnings results on Wednesday, May 5th. The company reported ($0.06) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). The business had revenue of $18.75 million for the quarter. Inotiv had a negative net margin of 5.52% and a negative return on equity of 47.67%.
NOTV stock traded down $0.06 during trading on Friday, reaching $28.94. The stock had a trading volume of 1,420 shares, compared to its average volume of 115,665. Inotiv has a 1-year low of $4.47 and a 1-year high of $30.43. The company has a debt-to-equity ratio of 2.54, a current ratio of 0.50 and a quick ratio of 0.47. The firm has a market capitalization of $458.06 million, a P/E ratio of -87.88 and a beta of 2.12. The company has a fifty day moving average of $23.92.
Large investors have recently made changes to their positions in the stock. Alpha Paradigm Partners LLC bought a new stake in shares of Inotiv during the 1st quarter valued at about $44,000. Dorsey Wright & Associates bought a new position in Inotiv in the 1st quarter worth about $47,000. O Shaughnessy Asset Management LLC bought a new position in Inotiv in the 1st quarter worth about $68,000. Legacy Wealth Planning LLC bought a new position in Inotiv in the 1st quarter worth about $210,000. Finally, Citadel Advisors LLC bought a new position in Inotiv in the 1st quarter worth about $252,000. 20.18% of the stock is owned by institutional investors and hedge funds.
Inotiv Company Profile
Inotiv, Inc provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products.
Featured Story: Momentum Indicator: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inotiv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotiv and related companies with MarketBeat.com's FREE daily email newsletter.